A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
Limited-Stage Small Cell Lung Cancer

About this trial
This is an interventional treatment trial for Limited-Stage Small Cell Lung Cancer focused on measuring Limited-Stage Small Cell Lung Cancer, Serplulimab
Eligibility Criteria
Inclusion Criteria:
- Male or female, aged ≥18 years when signing the ICF.
 - Histologically diagnosed with SCLC.
 - Diagnosed with LS-SCLC (stage Ⅰ-Ⅲ of the AJCC 8th edition of the cancer staging), which can be safely treated with curative radiation doses.
 - Major organs are functioning well.
 
Exclusion Criteria:
- Histologically or cytologically confirmed mixed SCLC.
 - Subjects suitable for surgery. Subjects who are suitable for surgery but refuse surgical treatment can be included.
 - Patients who have previously received systematic anti-tumor treatments for small cell lung cancer, including but not limited to radiotherapy, chemotherapy, and immunotherapy.
 - Patients with other active malignancies within 5 years or at the same time.
 - Subjects with known history of severe allergy to any monoclonal antibody.
 - Subjects with known anaphylaxis to carboplatin/cisplatin or etoposide.
 - In the judgment of the investigator, subjects who have any other factors that may lead to a premature discontinuation.
 
Sites / Locations
- OPN-GlendaleRecruiting
 - OPN-Los AlamitosRecruiting
 - Southern California Permanente GroupRecruiting
 - Emad Ibrahim, MD, IncRecruiting
 - Providence Medical FoundationRecruiting
 - Lutheran Medical Center - Cancer Centers of Colorado
 - Eastern Connecticut Hematology & Oncology AssociatesRecruiting
 - Cancer Specialists of North FloridaRecruiting
 - Mid Florida Hematology and Oncology CenterRecruiting
 - Advent Health OrlandoRecruiting
 - Napa Research
 - Kansas University Mediacal Center
 - Pontchartrain Cancer CenterRecruiting
 - Tulane UniversityRecruiting
 - Health PartnersRecruiting
 - Renown HealthRecruiting
 - Dartmouth Hitchcock Medical CenterRecruiting
 - Montefiore Medical CenterRecruiting
 - New York City Health+HospitalsCorporation Elmhurst Hospital Center
 - Northwell Health
 - Cleveland Clinic Mercy HospitalRecruiting
 - Gabrail Cancer Center
 - Tricounty Hematology and Oncology AssociatesRecruiting
 - Kaiser Permanente NorthwestRecruiting
 - The Center for Cancer and Blood DisordersRecruiting
 - Millennium Research & Clinical DevelopmentRecruiting
 - Pro Research Tools, INC DBA Lumi ResearchRecruiting
 - The University of Texas - Hope Cancer CenterRecruiting
 - Innova Schar Cancer Insitute
 - Northwest Medical SpecialtiesRecruiting
 - Klinikum Klagenfurt am Worthersee
 - Klinikum Klagenfurt am Wörthersee
 - Karl Landsteiner Institut für Lungenforschung und pneumologische Onkologie, c/o Klinik Floridsdorf Abteilung für Innere Medizin und Pneumologie
 - Karl Landsteiner Institute for Lung Research and Pneumological Oncology, c/o Klinik Floridsdorf Department for Inner Medicine und Pneumology
 - The First Affiliated Hospital of Bengbu Medical College
 - Anhui Chest Hospital
 - Cancer Hospital Chinese Academy of Medical Sciences
 - Beijing Cancer Hospital
 - The First Affiliated Hospital of Chongqing Medical
 - Chongqing University Cancer Hospital
 - Fujian Cancer Hospital
 - The First Affiliated Hospital of Guangdong Pharmaceutical University
 - Sun Yat-Sen University Cancer Center
 - Peking University Shenzhen Hospital
 - The Second Affiliated Hospital of Guilin Medical University
 - Guangxi Medical University Cancer Hospital
 - Gungzhouyikedaxuefushuzhongliuyiyuan
 - Affiliated Hospital of Hebei University
 - Cangzhou People's Hospital
 - Tangshan People's Hospital
 - Harbin Medical University Cancer Hospital
 - Jiamusi Cancer Hospital
 - The First Affiliated Hospital of Henan University of Science and Technology
 - The First Affiliated Hospital of Xinxiang Medical University
 - Henan Cancer Hospital
 - The First Affiliated Hospital of Zhengzhou University
 - Hong Kong United Oncology CentreRecruiting
 - Queen Elizabeth HospitalRecruiting
 - Queen Mary HospitalRecruiting
 - TaiHe Hospital Affiliated Hospital of Hubei University of Medicine
 - Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
 - Zhongnan hospital of wuhan university
 - Hubei Cancer Hospital
 - The First People's Hospital Of Changde City
 - The Second Xiangya Hospita
 - Hunan Cancer Hospital
 - Xiangya Hospital Central South University
 - Xuzhou Central Hospital
 - Northern Jiangsu people's Hospital
 - First Affiliated Hospital of Gannan Medical University
 - Ganzhou Cancer Hospital
 - The First Affiliated Hospital of Nanchang University
 - Jilin Cancer Hospital
 - Liaoning Cancer Hospital & Institute
 - Shenyang The Tenth People's Hospital
 - Qilu Hospital of Shandong University
 - Shandong Cancer Hospital
 - Linyi Tumor Hospital
 - Affiliated Hospital of Qingdao University
 - Shanghai Chest Hospital
 - Fudan University Shanghai Cancer Center
 - Zhongshan Hospital of Fudan University
 - Wenzhou University Hospital
 - Baoji Central Hospital
 - Shanxi Provincial Cancer Hospital
 - First Affiliated Hospital of Xi'an Jiaotong University
 - West China Hospital of Sichuan University
 - Tianjin Medical University Cancer Institute & Hospital
 - Tianjin Medical University General Hospital
 - The Second People's Hospital Of Yibin
 - Yunnan Cancer Hospital
 - Sir Run Run Shaw Hospital Zhejiang University School of Medicine
 - Yuhang Branch of the First Affiliated Hospital of Zhejiang University
 - Zhejiang Cancer Hospital
 - The Second Affiliated Hospital Zhejiang University School of Medicine
 - Taizhou Hospital of Zhejiang Province
 - The 1st Affiliated Hospital of WMU
 - University Hospital Brno (Clinic For Lung Diseases and Tuberculosis)
 - University Hospital Brno
 - University Hospital Olomouc (Oncology Clinic)
 - University Hospital Ostrava (oncology department)
 - University Hospital Ostrava
 - Nemocnice AGEL Ostrava-Vítkovice
 - Nemocnice AGEL Ostrava-Vítkovice
 - University Hospital Motol
 - University Hospital Motol (Pneumology Clinic 2.LF UK and FN Motol)
 - General University hospital in Prague (Oncology department)
 - Kliniken der Stadt Cologne GmbH
 - University hospital Schleswig-Holstein
 - "Sotiria" Thoracic Diseases General Hospital of Athens
 - General Hospital of Athens "Alexandra"
 - Fejer County Szent Gyorgy University Teaching Hospital
 - Pulmonary Institute of Torokbalint
 - Riga East University Hospital, Latvian Oncology Center
 - Clinic of Oncology, Pauls Stradins Clinical university hospital
 - Hospital St. Jansdal
 - Isala Hospital
 - MedPoloniaSp. z o.o.
 - Lung and Chest Cancer Clinic, National Institute of Oncology
 - Hospital German Trias i Pujol/ ICO Badalona
 - University Hospital La Fe
 
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Serplulimab + carboplatin/cisplatin-etoposide + radiotherapy
placebo + carboplatin/cisplatin-etoposide + radiotherapy
Participants will receive 4 cycles of standard-of-care chemotherapy (carboplatin/cisplatin-etoposide) plus Serplulimab 300 mg every 3 weeks (Q3W) concurrently with standard thoracic radiotherapy, with maximum 1 year after completion of cCRT or until disease progression, intolerable toxicity or other reasons specified in the protocol, whichever occurs first.
Participants will receive 4 cycles of standard-of-care chemotherapy (carboplatin/cisplatin-etoposide) plus placebo every 3 weeks (Q3W) concurrently with standard thoracic radiotherapy, with maximum 1 year after completion of cCRT or until disease progression, intolerable toxicity or other reasons specified in the protocol, whichever occurs first.